Equities

Shanghai Pioneer Holding Ltd

Shanghai Pioneer Holding Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)1.85
  • Today's Change-0.05 / -2.63%
  • Shares traded2.00k
  • 1 Year change-23.87%
  • Beta0.2038
Data delayed at least 15 minutes, as of May 02 2024 08:58 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Shanghai Pioneer Holding Ltd, formerly China Pioneer Pharma Holdings Ltd, is a China-based investment holding company mainly engaged in the marketing, promotion and sales of pharmaceutical products, medical devices and personal protective equipment. The Company operates mainly through three segments. The Products Sold via the Provision of Channel Management Services segment is principally engaged in the sales of the Company's ophthalmic pharmaceutical products to customers through pipeline management arrangements. The Products Sold via the Provision of Comprehensive Marketing, Promotion and Channel Management Services segment is principally engaged in the sale of all of the Company's pharmaceutical products and medical devices to customers through comprehensive marketing, promotion and channel management arrangements. The Sales of Personal Protective Materials segment is mainly engaged in the sales of personal protective materials include masks, protective gloves and protective suits.

  • Revenue in HKD (TTM)1.69bn
  • Net income in HKD157.46m
  • Incorporated2013
  • Employees345.00
  • Location
    Shanghai Pioneer Holding LtdNo. 15Lane 88, Wuwei Road, Putuo DistrictSHANGHAI 201201ChinaCHN
  • Phone+86 2 150498986
  • Fax+86 2 150498986
  • Websitehttp://www.pioneer-pharma.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Salus Ljubljana dd4.15bn109.73m1.76bn144.0015.862.8111.920.4231125.46125.464,748.71707.472.889.888.30--7.626.5115.8213.2910.868.662.642.370.8977121.660.181760.888.1616.330.68727.7330.8114.87
Amway (Malaysia) Holdings Berhad2.31bn190.03m1.95bn345.0010.243.869.080.84280.70520.70528.571.872.416.3429.624,081,910.0019.8812.9740.1827.1624.7621.368.235.021.31229.800.032588.80-7.037.6950.7916.297.920.00
TTK Healthcare Ltd704.70m60.91m2.08bn1.29k34.07--28.472.9546.0043.54532.21--------5,810,471.00--5.08--7.7654.6855.288.644.45--9.81--35.1621.014.66141.3219.7221.4414.87
Shanghai Kai Kai Industrial Co Ltd999.42m42.46m2.11bn492.0064.244.24--2.110.16170.16173.812.450.72929.043.491,880,224.003.232.395.303.5320.1923.544.433.201.23--0.167826.333.461.06-1.572.2134.011.72
Shanghai Pioneer Holding Ltd1.69bn157.46m2.39bn345.0014.202.1914.931.410.13360.13361.440.86491.012.433.294,906,997.008.328.9011.9412.4942.6548.698.239.091.56472.580.067865.470.6833-0.7199-38.0711.49----
CM Hospitalar SA16.69bn542.09m2.45bn7.00k4.360.49042.620.14681.161.1637.4010.281.125.714.951,583,404.003.654.005.346.1515.6415.893.253.501.311.620.5096--26.7233.2238.5760.22-2.72--
Beihai Gofar Chuanshan Biological Co Ltd383.69m-99.41m2.65bn463.00--2.86--6.91-0.1755-0.17550.67751.630.32583.171.49767,059.10-8.32-0.517-9.99-0.620822.8924.59-25.54-1.442.60-63.640.0336---19.6910.46-336.10---17.59--
Medios AG14.95bn157.61m2.82bn515.0017.890.7198.460.18890.79150.791574.9619.693.0530.6415.413,465,445.003.213.403.744.076.146.051.051.012.5218.750.0359--10.8040.342.6234.17-7.11--
Jiangsu Lianhuan Pharmaceutical Co. Ltd2.35bn145.86m2.87bn1.30k19.691.96--1.220.47170.47177.594.740.78063.864.451,677,547.005.435.9310.9311.2547.2253.266.967.820.83277.410.346430.6411.2016.36-4.5012.919.3513.97
Enseval Putera Megatrading Tbk PT13.72bn331.25m2.95bn5.12k8.900.84457.080.2147254.03254.0310,517.092,676.112.676.867.425,573,387,000.006.457.639.4510.8010.2210.712.412.861.52551.570.0188--1.716.71-18.761.068.20--
Data as of May 02 2024. Currency figures normalised to Shanghai Pioneer Holding Ltd's reporting currency: Hong Kong Dollar HKD

Institutional shareholders

0.50%Per cent of shares held by top holders
HolderShares% Held
Dimensional Fund Advisors LPas of 04 Apr 20245.68m0.45%
Jennison Associates LLCas of 30 Sep 2023209.00k0.02%
American Century Investment Management, Inc.as of 04 Apr 2024145.00k0.01%
Schroder Investment Management North America, Inc.as of 30 Jun 2019119.00k0.01%
Russell Investments Ltd.as of 30 Sep 202394.71k0.01%
Dimensional Fund Advisors Ltd.as of 29 Feb 202450.85k0.00%
DFA Australia Ltd.as of 31 Dec 202326.12k0.00%
LGT Capital Partners AG (Investment Management)as of 31 May 20235.00k0.00%
More ▼
Data from 31 Dec 2023 - 25 Apr 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.